Full-Time

Human Resources Manager

Posted on 5/17/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$99.1k - $129.4k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

New Albany, OH, USA

Category
Human Resources
People & HR
Required Skills
Data Analysis
Requirements
  • Doctorate degree
  • Master’s degree and 2 years of HR Business Partner experience
  • Bachelor’s degree and 4 years of HR Business Partner experience
  • Associate's degree and 8 years of HR Business Partner experience
  • High school diploma / GED and 10 years of HR Business Partner experience
Responsibilities
  • Drive organizational design / optimization strategies in partnership with client leaders to provide a flexible and capable workforce to meet needs of today and future business of site
  • Partner with client leaders to implement cutting edge strategies to drive innovation, growth, employee engagement, and diversity, inclusion and belonging
  • Support the global delivery of HR initiatives, identifying and managing opportunities in assigned client group to support the achievement of strategic goals
  • Collaborate with client leaders on site-specific staffing strategies; continue to build community outreach to help build our external talent pipeline
  • Provide ongoing guidance and advice for site Apprenticeship program
  • Partner with program leads, liaisons, and key business partners to implement Operations and global HR development programs
  • Develop and implement innovative ideas to build engagement and a strong culture in an evolving landscape
  • In partnership with the HR Site Head, create and manage new and innovative tools to increase the efficiency and effectiveness of the site HR organization
  • Develop strong partnerships with HR centers of excellence (COEs) and effectively leverage these relationships to oversee leadership development, talent management, staff engagement and retention
  • Analyze HR key metrics and use data to develop proposals for targeted HR talent strategies
  • Stay current on leading HR trends and deliver practical and insightful recommendations, including the development and personal growth of our people
  • Ad hoc projects and assignments based on business needs
Desired Qualifications
  • 6+ years of progressively complex/strategic HR experience, including organization effectiveness, recruitment, talent development, compensation or staff relations
  • Demonstrated ability to balance multiple competing priorities, adapt to ever changing demands
  • Possess an intellectual curiosity, desire, and ability to quickly learn and understand the business
  • Excellent communication and interpersonal skills
  • Demonstrated ability to interact, influence, and build relationships with all levels of management and executives
  • Highly organized and can deliver on multiple priorities
  • Demonstrated comfort with ambiguity and organizational change
  • A strong aptitude to have meaningful impact for the better, and have fun while doing it
  • Willingness to “speak up” and respectfully challenge existing approaches to drive continuous change
  • Continuous improvement and growth learning mindset

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The company's goal is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

INACTIVE